ExtraSuperTadarise is a compound preparation whose main ingredients include Tadalafil and Dapoxetine. It is used for the treatment of male erectile dysfunction (ED) and premature ejaculation (PE).
How Effective is ExtraSuperTadarise?
Efficacy in Treating Erectile Dysfunction
Tadalafil, an ingredient in ExtraSuperTadarise, is a long-acting PDE5 inhibitor that can significantly improve erectile function.
Clinical studies have shown that this medication can increase blood flow to the penis under sexual stimulation, helping to achieve and maintain sufficient erectile hardness.
It has a relatively long duration of action, providing a more flexible time window for sexual activity.
Efficacy in Treating Premature Ejaculation
Dapoxetine, another ingredient, is a selective serotonin reuptake inhibitor (SSRI) that can prolong the ejaculatory latency period.
Clinical observations have indicated that this medication can help control ejaculation time, alleviate premature ejaculation symptoms, and improve the quality of sexual life.
The two ingredients work synergistically to comprehensively improve male sexual dysfunction.
Comprehensive Therapeutic Efficacy
Through its dual effects, ExtraSuperTadarise can not only address erectile issues but also extend intercourse duration, providing a comprehensive solution for patients with both ED and PE.
Its therapeutic efficacy has been verified in clinical practice, significantly enhancing patients' sexual satisfaction and quality of life.
Indicated and Contraindicated Populations for ExtraSuperTadarise
Characteristics of Target Patients
Adult males aged 18 years and above.
Patients with both erectile dysfunction and premature ejaculation.
Patients who have poor responses to single-ingredient treatments and require combination therapy.
Contraindicated Populations
Patients currently using any form of nitrate medications.
Patients with severe cardiovascular diseases or unstable angina pectoris.
Patients allergic to Tadalafil or Dapoxetine.
Patients with severe liver function impairment.
Medication Monitoring for ExtraSuperTadarise
Pre-Treatment Evaluation
Comprehensive cardiovascular system assessment.
Liver and kidney function tests.
Detailed medication history review to avoid potential drug interactions.
Evaluation of erectile function and ejaculation control ability.
Key Monitoring Items During Treatment
Cardiovascular monitoring: Pay attention to changes in blood pressure and cardiac symptoms.
Liver function monitoring: Conduct regular checks of liver enzyme indicators.
Central nervous system monitoring: Watch for adverse reactions such as dizziness and drowsiness.
Vision monitoring: Be alert to abnormal color perception or changes in vision.
Mental state monitoring: Assess emotional changes and depressive symptoms.
Special Monitoring Requirements
Close observation for adverse reactions is required after the first dose.
When used in combination with CYP3A4 inhibitors, monitoring of drug concentration is necessary.
Regular efficacy evaluation for long-term users.
Immediate medical attention is required if priapism (abnormal erection) lasts for more than 4 hours.
